.jpg "Selecta Biosciences (NASDAQ: SELB)")
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB), with a price target of $30. The company’s shares closed yesterday at $14.70.
Yang wrote:
“We think this is likely a catalyst for the shares and we view the probability of success as favorable. Management is hosting a conference call at 8:00 AM ET on to discuss the data.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 23.3% and a 53.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Selecta Biosciences is a Strong Buy with an average price target of $31.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.46 and a one-year low of $7.95. Currently, Selecta Biosciences has an average volume of 120.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
